MiniMed

Q1 FY2027 EarningsQ1 FY27 results delivered a top-line beat but a bottom-line miss compared to consensus. Revenue of $843M exceeded the $828.4M estimate (+1.8% variance), driven by strong international sales and the U.S. launch of MiniMed Flex. However, normalized EPS of $0.00 was significantly below the $0.096 expected, primarily due to an effective tax rate of 96.7% vs. the 19.5% consensus and higher-than-expected transition costs following the Separation. While operational momentum in CGM and AID systems remains robust, significant non-operational headwinds and separation expenses pressured the bottom line.